Neutrophil extracellular traps (NETs) contribute to the pathogenesis of multiple autoimmune diseases. And research has shown that patients with antiphospholipid syndrome (APS) have higher levels of circulating anti-NET antibodies than healthy controls, indicating a potential biomarker.
Neurosarcoidosis & sarcoid dermatopathology are discussed.
During the ACR Convergence 2021 Review Course, Rohit Aggarwal, MD, MS, provided an update on idiopathic inflammatory myopathy.
ACR CONVERGENCE 2021—Hematologic abnormalities are common in systemic lupus erythematosus (SLE), whether due to SLE itself or something else. As rheumatology professionals, we are routinely challenged by the management of cytopenias in our SLE patients. At the ACR’s annual meeting in 2021, two hematologists shared expert advice regarding common hematologic manifestations of SLE. Michael B….
Labial salivary gland biopsy (i.e., lip biopsy) is a useful tool to help diagnose Sjögren’s syndrome in suspected patients, but most rheumatologists are not trained to perform the minimally invasive procedure. A new, 40-minute training video and slide presentation with step-by-step instructions may help them fill that critical skill gap. Two rheumatologists collaborated to create…
Michael B. Brenner, MD, addresses exciting advances in basic science in rheumatology, including insights into inflammation in osteoarthritis, the adult-onset autoinflammatory syndrome VEXAS and more.
Gendron et al. undertook this study to investigate the prevalence and prognostic value of conventional and nonconventional antiphospholipid antibodies in patients with COVID-19.
New and updated FY22 diagnosis codes became effective for encounters on or after Oct. 1, 2021, including key updates for Sjögren syndrome and non-radiographic axial spondyloarthritis.
Sarcoidosis and IgG4-related disease (IgG4-RD) are both immune-mediated, often multi-organ, diseases of uncertain etiology capable of presenting with diverse clinical manifestations. Many clinical features are common to both conditions, including hypergammaglobulinemia, the ability to form inflammatory masses and involvement of the lymph nodes, lacrimal glands, salivary glands, meninges and lungs. Although imaging modalities, such as…
NEW YORK (Reuters Health)—Rituximab seemed to be a safe and effective treatment for systemic sclerosis (SSc) in a placebo-controlled validation trial in Japan.1 “A number of studies have examined B-cell depletion therapy for systemic sclerosis, and many of them have suggested that [this] is effective in treating systemic sclerosis,” Ayumi Yoshizaki, MD, tells Reuters Health…